PROFILPELAJAR.COM

Suntinorexton
Clinical data
Routes of; administration	By mouth
Identifiers
	IUPAC name N-[(2S,3S)-2-[[2-fluoro-3-(3-fluorophenyl)phenyl]methyl]-1-(2-hydroxy-2-methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide;
CAS Number	2274802-89-8 ;
PubChem CID	137460941;
UNII	FF2NQ35DA4;
Chemical and physical data
Formula	C23H28F2N2O4S
Molar mass	466.54 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCS(=O)(=O)N[C@H]1CCN([C@H]1CC2=C(C(=CC=C2)C3=CC(=CC=C3)F)F)C(=O)C(C)(C)O;
	InChI InChI=1S/C23H28F2N2O4S/c1-4-32(30,31)26-19-11-12-27(22(28)23(2,3)29)20(19)14-16-8-6-10-18(21(16)25)15-7-5-9-17(24)13-15/h5-10,13,19-20,26,29H,4,11-12,14H2,1-3H3/t19-,20-/m0/s1; Key:MQDUVMBBJZLFHF-PMACEKPBSA-N;

Suntinorexton (INNTooltip International Nonproprietary Name; developmental code name TAK-861) is an experimental orexin receptor agonist.^[1]^[2] It acts as a selective agonist of the orexin OX₂ receptor and was described in 2019 in a patent by Takeda Pharmaceutical Company.^[3] Suntinorexton superseded firazorexton (TAK-994) as a clinical drug candidate following evidence of hepatoxicity in humans.^[1] The drug has reached phase 3 clinical trials as of 2024.^[1]^[4] It is orally active and centrally penetrant.^[1]

References

^ ^a ^b ^c ^d ^e Konofal, Eric (2024). "From past to future: 50 years of pharmacological interventions to treat narcolepsy". Pharmacology Biochemistry and Behavior. 241: 173804. doi:10.1016/j.pbb.2024.173804.
^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 34 (1): 93–269. 2020. Proposed INN: List 123
^ WO application 2019027058, Kajita Y, Mikami S, Miyanohana Y, Koike T, Daini M, Oyabu N, Ogino M, Takeuchi K, Ito Y, Tokunaga N, Sugimoto T, Miyazaki T, Oda T, Hoashi Y, Hattori Y, Imamura K, "Heterocyclic compound and use therof", published 2019-02-07, assigned to Takeda Pharmaceutical Company.
^ "TAK 861". AdisInsight. 12 July 2024. Retrieved 30 July 2024.